Trametinib improved progression-free survival (PFS) over the standard of care (SOC) of therapy for patients with recurrent low-grade serous ovarian cancer (LGSOC) was demonstrated in the GOG 281/LOGS study. The purpose of this research was to compare the costs associated with trametinib with the current standard of therapy for recurrent LGSOC among US payers.
Trametinib’s efficacy and cost in patients with recurrent LGSOC were compared to those of a standard-of-care group using a Markov model. Life years (LYs), quality-adjusted LYs (QALYs), lifetime costs, and incremental cost-effectiveness ratios (ICERs) were all determined. One-way and probabilistic sensitivity assessments were undertaken to evaluate the model’s robustness. Trametinib group provided an additional 0.58 QALYs (1.14 LYs) and an added cost of $248,214 compared with the SOC group. The increased cost-effectiveness ratio was $424,097 per QALY. This model appeared to be sensitive to the hazard ratio of OS and PFS between the trametinib and SOC group, the utility of PFS, and the cycle cost of trametinib, according to the findings of one-way sensitivity analyses.
According to probabilistic sensitivity analysis, there was a 6% chance that the trametinib group would be cost-effective at a willingness-to-pay (WTP) threshold of $150,000 per QALY. At an anticipated WTP threshold of $150,000 per QALY, trametinib is not cost-effective for patients with recurrent LGSOC from the standpoint of US payers. If trametinib prices drop, it will likely become more cost-effective for people with recurrent LGSOC.